Abstract

Ubiquitin-specific protease 14 (USP14), a deubiquitinating enzyme (DUB), is associated with proteasomes and exerts a dual function in regulating protein degradation. USP14 protects protein substrates from degradation by removing ubiquitin chains from proteasome-bound substrates, whereas promotes protein degradation by activating the proteasome. Increasing evidence have shown that USP14 is involved in several canonical signaling pathways, correlating with cancer, neurodegenerative diseases, autophagy, immune responses, and viral infections. The activity of USP14 is tightly regulated to ensure its function in various cellular processes. Structural studies have demonstrated that free USP14 exists in an autoinhibited state with two surface loops, BL1 and BL2, partially hovering above and blocking the active site cleft binding to the C-terminus of ubiquitin. Hence, both proteasome-bound and phosphorylated forms of USP14 require the induction of conformational changes in the BL2 loop to activate its deubiquitinating function. Due to its intriguing roles in the stabilization of disease-causing proteins and oncology targets, USP14 has garnered widespread interest as a therapeutic target. In recent years, significant progress has been made on identifying inhibitors targeting USP14, despite the complexity and challenges in improving their selectivity and affinity for USP14. In particular, the crystal structures of USP14 complexed with IU1-series inhibitors revealed the underlying allosteric regulatory mechanism and enabled the further design of potent inhibitors. In this review, we summarize the current knowledge regarding the structure, regulation, pathophysiological function, and selective inhibition of USP14, including disease associations and inhibitor development.

Highlights

  • Ubiquitination is an essential posttranslational modification process in both prokaryotic and eukaryotic cells, whereby substrate protein is covalently attached to ubiquitin through isopeptide bonds catalyzed by the E1-E2-E3 ligase cascade to be marked for degradation (Schulman and Harper, 2009; Ye and Rape, 2009; Buetow and Huang, 2016)

  • Genetic silencing of Ubiquitin-specific protease 14 (USP14) increased the sensitivity of Gastric cancer (GC) cells to cisplatin and led to cisplatin-induced apoptosis by inactivating the Akt and ERK signaling pathways (Table 2) (Zhu et al, 2017). These results revealed that USP14 could potentially serves as both a prognostic marker and therapeutic target for patients with GC

  • Transgenic overexpression of ubiquitin in neurons of axJ mice was shown to prevent early postnatal lethality, restore muscle mass, and correct deficits resulting from the loss-of-function of USP14 (Chen et al, 2011). These results suggested the reason for the dramatic disorder in axJ mice following the loss of USP14 and further demonstrated that USP14 is required for maintaining ubiquitin homeostasis during synaptic development and function (Chen et al, 2011)

Read more

Summary

Introduction

Ubiquitination is an essential posttranslational modification process in both prokaryotic and eukaryotic cells, whereby substrate protein is covalently attached to ubiquitin through isopeptide bonds catalyzed by the E1-E2-E3 ligase cascade to be marked for degradation (Schulman and Harper, 2009; Ye and Rape, 2009; Buetow and Huang, 2016). Promote the ubiquitination and degradation of AR, and suppress PC cell proliferation via arresting that in G0/G1 phase Arrested cell cycle and decreased the lung cell proliferation, migration, and invasion Increased sensitivity of GC cells to cisplatin by leading apoptosis through inactivating Akt and ERK signaling pathways Enhanced clearance of tau protein and ataxin-3

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call